Genes involved in prostate cancer progression determine MRI visibility

Ping Li, Sungyong You, Christopher Nguyen, Yanping Wang, Jayoung Kim, Deepika Sirohi, Asha Ziembiec, Daniel Luthringer, Shih Chieh Lin, Timothy Daskivich, Jonathan Wu, Michael R. Freeman, Rola Saouaf, Debiao Li, Hyung L. Kim

研究成果: Article

11 引文 (Scopus)

摘要

MRI is used to image prostate cancer and target tumors for biopsy or therapeutic ablation. The objective was to understand the biology of tumors not visible on MRI that may go undiagnosed and untreated. Methods: Prostate cancers visible or invisible on multiparametric MRI were macrodissected and examined by RNAseq. Differentially expressed genes (DEGs) based on MRI visibility status were cross-referenced with publicly available gene expression databases to identify genes associated with disease progression. Genes with potential roles in determining MRI visibility and disease progression were knocked down in murine prostate cancer xenografts, and imaged by MRI. Results: RNAseq identified 1,654 DEGs based on MRI visibility status. Comparison of DEGs based on MRI visibility and tumor characteristics revealed that Gleason score (dissimilarity test, p<0.0001) and tumor size (dissimilarity test, p<0.039) did not completely determine MRI visibility. Genes in previously reported prognostic signatures significantly correlated with MRI visibility suggesting that MRI visibility was prognostic. Cross-referencing DEGs with external datasets identified four genes (PHYHD1, CENPF, ALDH2, GDF15) that predict MRI visibility, progression free survival and metastatic deposits. Genetic modification of a human prostate cancer cell line to induce miR-101 and suppress CENPF decreased cell migration and invasion. As prostate cancer xenografts in mice, these cells had decreased visibility on diffusion weighted MRI and decreased perfusion, which correlated with immunostaining showing decreased cell density and proliferation. Conclusions: Genes involved in prostate cancer prognosis and metastasis determine MRI visibility, indicating that MRI visibility has prognostic significance. MRI visibility was associated with genetic features linked to poor prognosis.

原文English
頁(從 - 到)1752-1765
頁數14
期刊Theranostics
8
發行號7
DOIs
出版狀態Published - 2018 一月 1

指紋

Prostatic Neoplasms
Genes
Heterografts
Disease Progression
Neoplasms
Diffusion Magnetic Resonance Imaging
Neoplasm Grading
Disease-Free Survival
Cell Movement
Perfusion
Cell Count
Cell Proliferation
Databases
Neoplasm Metastasis
Biopsy
Gene Expression
Cell Line

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

引用此文

Li, P., You, S., Nguyen, C., Wang, Y., Kim, J., Sirohi, D., ... Kim, H. L. (2018). Genes involved in prostate cancer progression determine MRI visibility. Theranostics, 8(7), 1752-1765. https://doi.org/10.7150/thno.23180
Li, Ping ; You, Sungyong ; Nguyen, Christopher ; Wang, Yanping ; Kim, Jayoung ; Sirohi, Deepika ; Ziembiec, Asha ; Luthringer, Daniel ; Lin, Shih Chieh ; Daskivich, Timothy ; Wu, Jonathan ; Freeman, Michael R. ; Saouaf, Rola ; Li, Debiao ; Kim, Hyung L. / Genes involved in prostate cancer progression determine MRI visibility. 於: Theranostics. 2018 ; 卷 8, 編號 7. 頁 1752-1765.
@article{445efe345de84a69b7f473d9c6147f9b,
title = "Genes involved in prostate cancer progression determine MRI visibility",
abstract = "MRI is used to image prostate cancer and target tumors for biopsy or therapeutic ablation. The objective was to understand the biology of tumors not visible on MRI that may go undiagnosed and untreated. Methods: Prostate cancers visible or invisible on multiparametric MRI were macrodissected and examined by RNAseq. Differentially expressed genes (DEGs) based on MRI visibility status were cross-referenced with publicly available gene expression databases to identify genes associated with disease progression. Genes with potential roles in determining MRI visibility and disease progression were knocked down in murine prostate cancer xenografts, and imaged by MRI. Results: RNAseq identified 1,654 DEGs based on MRI visibility status. Comparison of DEGs based on MRI visibility and tumor characteristics revealed that Gleason score (dissimilarity test, p<0.0001) and tumor size (dissimilarity test, p<0.039) did not completely determine MRI visibility. Genes in previously reported prognostic signatures significantly correlated with MRI visibility suggesting that MRI visibility was prognostic. Cross-referencing DEGs with external datasets identified four genes (PHYHD1, CENPF, ALDH2, GDF15) that predict MRI visibility, progression free survival and metastatic deposits. Genetic modification of a human prostate cancer cell line to induce miR-101 and suppress CENPF decreased cell migration and invasion. As prostate cancer xenografts in mice, these cells had decreased visibility on diffusion weighted MRI and decreased perfusion, which correlated with immunostaining showing decreased cell density and proliferation. Conclusions: Genes involved in prostate cancer prognosis and metastasis determine MRI visibility, indicating that MRI visibility has prognostic significance. MRI visibility was associated with genetic features linked to poor prognosis.",
author = "Ping Li and Sungyong You and Christopher Nguyen and Yanping Wang and Jayoung Kim and Deepika Sirohi and Asha Ziembiec and Daniel Luthringer and Lin, {Shih Chieh} and Timothy Daskivich and Jonathan Wu and Freeman, {Michael R.} and Rola Saouaf and Debiao Li and Kim, {Hyung L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.7150/thno.23180",
language = "English",
volume = "8",
pages = "1752--1765",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "7",

}

Li, P, You, S, Nguyen, C, Wang, Y, Kim, J, Sirohi, D, Ziembiec, A, Luthringer, D, Lin, SC, Daskivich, T, Wu, J, Freeman, MR, Saouaf, R, Li, D & Kim, HL 2018, 'Genes involved in prostate cancer progression determine MRI visibility', Theranostics, 卷 8, 編號 7, 頁 1752-1765. https://doi.org/10.7150/thno.23180

Genes involved in prostate cancer progression determine MRI visibility. / Li, Ping; You, Sungyong; Nguyen, Christopher; Wang, Yanping; Kim, Jayoung; Sirohi, Deepika; Ziembiec, Asha; Luthringer, Daniel; Lin, Shih Chieh; Daskivich, Timothy; Wu, Jonathan; Freeman, Michael R.; Saouaf, Rola; Li, Debiao; Kim, Hyung L.

於: Theranostics, 卷 8, 編號 7, 01.01.2018, p. 1752-1765.

研究成果: Article

TY - JOUR

T1 - Genes involved in prostate cancer progression determine MRI visibility

AU - Li, Ping

AU - You, Sungyong

AU - Nguyen, Christopher

AU - Wang, Yanping

AU - Kim, Jayoung

AU - Sirohi, Deepika

AU - Ziembiec, Asha

AU - Luthringer, Daniel

AU - Lin, Shih Chieh

AU - Daskivich, Timothy

AU - Wu, Jonathan

AU - Freeman, Michael R.

AU - Saouaf, Rola

AU - Li, Debiao

AU - Kim, Hyung L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - MRI is used to image prostate cancer and target tumors for biopsy or therapeutic ablation. The objective was to understand the biology of tumors not visible on MRI that may go undiagnosed and untreated. Methods: Prostate cancers visible or invisible on multiparametric MRI were macrodissected and examined by RNAseq. Differentially expressed genes (DEGs) based on MRI visibility status were cross-referenced with publicly available gene expression databases to identify genes associated with disease progression. Genes with potential roles in determining MRI visibility and disease progression were knocked down in murine prostate cancer xenografts, and imaged by MRI. Results: RNAseq identified 1,654 DEGs based on MRI visibility status. Comparison of DEGs based on MRI visibility and tumor characteristics revealed that Gleason score (dissimilarity test, p<0.0001) and tumor size (dissimilarity test, p<0.039) did not completely determine MRI visibility. Genes in previously reported prognostic signatures significantly correlated with MRI visibility suggesting that MRI visibility was prognostic. Cross-referencing DEGs with external datasets identified four genes (PHYHD1, CENPF, ALDH2, GDF15) that predict MRI visibility, progression free survival and metastatic deposits. Genetic modification of a human prostate cancer cell line to induce miR-101 and suppress CENPF decreased cell migration and invasion. As prostate cancer xenografts in mice, these cells had decreased visibility on diffusion weighted MRI and decreased perfusion, which correlated with immunostaining showing decreased cell density and proliferation. Conclusions: Genes involved in prostate cancer prognosis and metastasis determine MRI visibility, indicating that MRI visibility has prognostic significance. MRI visibility was associated with genetic features linked to poor prognosis.

AB - MRI is used to image prostate cancer and target tumors for biopsy or therapeutic ablation. The objective was to understand the biology of tumors not visible on MRI that may go undiagnosed and untreated. Methods: Prostate cancers visible or invisible on multiparametric MRI were macrodissected and examined by RNAseq. Differentially expressed genes (DEGs) based on MRI visibility status were cross-referenced with publicly available gene expression databases to identify genes associated with disease progression. Genes with potential roles in determining MRI visibility and disease progression were knocked down in murine prostate cancer xenografts, and imaged by MRI. Results: RNAseq identified 1,654 DEGs based on MRI visibility status. Comparison of DEGs based on MRI visibility and tumor characteristics revealed that Gleason score (dissimilarity test, p<0.0001) and tumor size (dissimilarity test, p<0.039) did not completely determine MRI visibility. Genes in previously reported prognostic signatures significantly correlated with MRI visibility suggesting that MRI visibility was prognostic. Cross-referencing DEGs with external datasets identified four genes (PHYHD1, CENPF, ALDH2, GDF15) that predict MRI visibility, progression free survival and metastatic deposits. Genetic modification of a human prostate cancer cell line to induce miR-101 and suppress CENPF decreased cell migration and invasion. As prostate cancer xenografts in mice, these cells had decreased visibility on diffusion weighted MRI and decreased perfusion, which correlated with immunostaining showing decreased cell density and proliferation. Conclusions: Genes involved in prostate cancer prognosis and metastasis determine MRI visibility, indicating that MRI visibility has prognostic significance. MRI visibility was associated with genetic features linked to poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85042172342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042172342&partnerID=8YFLogxK

U2 - 10.7150/thno.23180

DO - 10.7150/thno.23180

M3 - Article

C2 - 29556354

AN - SCOPUS:85042172342

VL - 8

SP - 1752

EP - 1765

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 7

ER -

Li P, You S, Nguyen C, Wang Y, Kim J, Sirohi D 等. Genes involved in prostate cancer progression determine MRI visibility. Theranostics. 2018 1月 1;8(7):1752-1765. https://doi.org/10.7150/thno.23180